Alnylam Pharmaceuticals (ALNY), an RNAi therapeutics company, has signed a huge license with Roche which could be worth as much as $1 billion The small company had total revenue fo $26 million last year.
Under the terms of the agreeement: "Alnylam will give Roche a non-exclusive license to its technology. Roche will pay $331 million in upfront fees, including making an investment of just under 2 million shares of Alnylam stock, representing nearly 5 percent of the company’s outstanding shares," according to the AP.
Shares in ALNY are up 52% to $23.30, which takes the company’s market cap to $875 million.
The stock still looks cheap.
Douglas A. McIntyre
“The Next NVIDIA” Could Change Your Life
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
